Last reviewed · How we verify

Aromatase Inhibitors (Femara)

Dharmais National Cancer Center Hospital · Phase 3 active Small molecule

Aromatase Inhibitors (Femara) is a Aromatase inhibitor Small molecule drug developed by Dharmais National Cancer Center Hospital. It is currently in Phase 3 development for Hormone receptor-positive, HER2-negative early-stage breast cancer (adjuvant therapy), Metastatic hormone receptor-positive breast cancer, Extended therapy following tamoxifen in postmenopausal women. Also known as: Letrozole.

Femara (letrozole) inhibits the aromatase enzyme to block conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.

Femara (letrozole) inhibits the aromatase enzyme to block conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative early-stage breast cancer (adjuvant therapy), Metastatic hormone receptor-positive breast cancer, Extended therapy following tamoxifen in postmenopausal women.

At a glance

Generic nameAromatase Inhibitors (Femara)
Also known asLetrozole
SponsorDharmais National Cancer Center Hospital
Drug classAromatase inhibitor
TargetAromatase (CYP19A1)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Aromatase inhibitors like letrozole selectively block the cytochrome P450 aromatase enzyme, which catalyzes the final step of estrogen synthesis in postmenopausal women. By reducing circulating estrogen levels, these agents deprive estrogen receptor-positive breast cancer cells of growth signals. This mechanism is particularly effective in hormone-dependent breast cancers where estrogen drives proliferation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aromatase Inhibitors (Femara)

What is Aromatase Inhibitors (Femara)?

Aromatase Inhibitors (Femara) is a Aromatase inhibitor drug developed by Dharmais National Cancer Center Hospital, indicated for Hormone receptor-positive, HER2-negative early-stage breast cancer (adjuvant therapy), Metastatic hormone receptor-positive breast cancer, Extended therapy following tamoxifen in postmenopausal women.

How does Aromatase Inhibitors (Femara) work?

Femara (letrozole) inhibits the aromatase enzyme to block conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.

What is Aromatase Inhibitors (Femara) used for?

Aromatase Inhibitors (Femara) is indicated for Hormone receptor-positive, HER2-negative early-stage breast cancer (adjuvant therapy), Metastatic hormone receptor-positive breast cancer, Extended therapy following tamoxifen in postmenopausal women.

Who makes Aromatase Inhibitors (Femara)?

Aromatase Inhibitors (Femara) is developed by Dharmais National Cancer Center Hospital (see full Dharmais National Cancer Center Hospital pipeline at /company/dharmais-national-cancer-center-hospital).

Is Aromatase Inhibitors (Femara) also known as anything else?

Aromatase Inhibitors (Femara) is also known as Letrozole.

What drug class is Aromatase Inhibitors (Femara) in?

Aromatase Inhibitors (Femara) belongs to the Aromatase inhibitor class. See all Aromatase inhibitor drugs at /class/aromatase-inhibitor.

What development phase is Aromatase Inhibitors (Femara) in?

Aromatase Inhibitors (Femara) is in Phase 3.

What are the side effects of Aromatase Inhibitors (Femara)?

Common side effects of Aromatase Inhibitors (Femara) include Hot flashes, Arthralgia/joint pain, Fatigue, Headache, Osteoporosis/bone loss, Vaginal dryness.

What does Aromatase Inhibitors (Femara) target?

Aromatase Inhibitors (Femara) targets Aromatase (CYP19A1) and is a Aromatase inhibitor.

Related